Just over a year after Glycosorb® ABO was used for the first time in
In
Now, just over a year later, their initial experience on how the company's product has successfully facilitated three blood group incompatible kidney transplants from living donors has been published. The conclusion is that Glycosorb® ABO is effective and enables blood group incompatible kidney transplants to be performed successfully in a South African setting.
In addition to blood group incompatible kidney transplants from living donors, Glycosorb® ABO is also used in
In
1: Barday ZA. ABO-incompatible kidney transplantation using immunoadsorption columns: First experiences in
For more information, please contact:
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230
Brief information about the company
The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 25 countries, with
Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 6,500 transplants in over 25 countries.
The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.
https://news.cision.com/glycorex-transplantation/r/first-publication-from-south-africa-and-first-stem-cell-transplantation-performed-in-mexico,c3975823
https://mb.cision.com/Main/15286/3975823/2786265.pdf
(c) 2024 Cision. All rights reserved., source